{"id":"W3024082028","doi":"10.1007/s10637-020-00928-z","title":"A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Cetuximab; Medicine; KRAS; Colorectal cancer; Pharmacodynamics; Internal medicine; Adverse effect; Oncology; Pharmacokinetics; Response Evaluation Criteria in Solid Tumors; EGFR inhibitors; Epidermal growth factor receptor; Toxicity; Phases of clinical research; Cancer; Monoclonal antibody; Pharmacology; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005418191,0.000336108,0.0007123938,0.00007642763,0.0001554298,0.00002442174,0.00009736738,0.00004341243,0.00001506414],"category_scores_gemma":[0.00004237801,0.000188071,0.0001016807,0.0006520842,0.0001844439,0.0001365827,0.00005596695,0.0001407824,0.000001091583],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003321595,"about_ca_system_score_gemma":0.0008080453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00127838,"about_ca_topic_score_gemma":0.0004791337,"domain_scores_codex":[0.998052,0.00009596757,0.0003942838,0.0004362275,0.0007738406,0.0002477],"domain_scores_gemma":[0.9991069,0.00009498,0.0002488495,0.0001360947,0.0002042995,0.0002088934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006424026,0.009035766,0.9587798,0.00003703019,0.001792135,0.00004956302,0.02150825,0.0001045278,0.0007393326,0.00003710561,0.0001592702,0.001333265],"study_design_scores_gemma":[0.09942861,0.04201971,0.8422481,0.0004358812,0.0009088975,0.000002134422,0.001970433,0.0002429189,0.01237981,0.00002442819,0.00006069239,0.0002784202],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938509,0.000141866,0.000001664971,0.002539792,0.00006372836,0.003088813,0.0001533482,0.00002986863,0.0001300258],"genre_scores_gemma":[0.998436,0.00000380542,0.0004715912,0.0004174366,0.00007610545,0.0003465303,0.0001687374,0.00003131936,0.00004851533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1165317,"threshold_uncertainty_score":0.7669311,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01769703272519022,"score_gpt":0.2963037684540168,"score_spread":0.2786067357288266,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}